Immunome, Inc.

US$18.71As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:IMNMHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 8.66%
Div yield —
ROE (64.03%)
Biotechnology
Beta (5Y) 2.66
PE TTM —
TSR TTM 16.43%
Mkt cap US$2.208B
ROIC (40.53%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$20
8.73%
(6.89%)
Hold 3|11|3|4|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.14
0.14
0.13
0.15
(8.68%)
(3.27%)
(2.34%)
11.58%
Revenue$M
172.7
181.3
181.6
189.3
(1.94%)
2.10%
3.18%
8.85%
Peers (US$2.208B)
Cap (US$)
PE
2.187B
—
Capital
TTM
5Y
10Y
Leveragex
1.923
(0.048)
(0.044)
EBIT/Intx
0.918
1.348
1.430
Own earn%
(50.09)
(81.32)
(63.80)
Sh yield%
24.88
20.99
23.07
Owners
Insiders/Inst%
8.25
56.97
Short interest%
4.05
SBC / revenue%
1.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
24–32
$1 testx
—
Incr. ROIC%
25